Disease · MONDO_0024331

colorectal carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. colorectal carcinoma. Diseases, record MONDO_0024331. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0024331

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: colorectal carcinoma; Open Targets
Open Targets ID: MONDO_0024331; Open Targets
Other names: CRC, cancer of large bowel, cancer of large intestine, cancer of the large bowel, cancer of the large intestine, carcinoma of colorectum, carcinoma of large bowel, carcinoma of large intestine, carcinoma of the large bowel, carcinoma of the large intestine, colorectal (colon or rectal) cancer, colorectal cancer, colorectum carcinoma, large bowel cancer, large bowel carcinoma, large intestine cancer, large intestine carcinoma; Open Targets
Disease Ontology: DOID:0080199; Disease Ontology
NCI Thesaurus: C2955; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 125 drugs, from DailyMed and PMDA; Open Targets

Drugs125

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CETUXIMAB	CHEMBL1201577	Antibody	Approval	PMDA	22	21	21	Drugs and targets
TUCATINIB	CHEMBL3989868	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	38	38	31	Drugs and targets
IRINOTECAN	CHEMBL481	Small molecule	Phase 3	ClinicalTrials.gov	25	25	24	Drugs and targets
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 3	ClinicalTrials.gov	25	25	21	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 3	ClinicalTrials.gov	19	19	19	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 3	ClinicalTrials.gov	18	18	17	Drugs and targets
LEUCOVORIN CALCIUM	CHEMBL1201138	Small molecule	Phase 3	ClinicalTrials.gov	14	14	10	Drugs and targets
LEUCOVORIN	CHEMBL1679	Small molecule	Phase 3	ClinicalTrials.gov	12	12	11	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets

1 to 10 of 125

See all 125 drugs

Targets178

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	11	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	8	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	7	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2321	Drugs and targets
PDCD1	Programmed cell death protein 1	7	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	6	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2/3	https://conductscience.org/library/genes/5159	Drugs and targets
EGFR	Epidermal growth factor receptor	5	Epidermal growth factor receptor erbB1 antagonist; Epidermal growth factor receptor erbB1 inhibitor	Approval	https://conductscience.org/library/genes/1956	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	5	Stem cell growth factor receptor inhibitor	Phase 2/3	https://conductscience.org/library/genes/3815	Drugs and targets
BRAF	Serine/threonine-protein kinase B-raf	4	Serine/threonine-protein kinase B-raf inhibitor	Phase 2/3	https://conductscience.org/library/genes/673	Drugs and targets
FGFR1	Fibroblast growth factor receptor	4	Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2260	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	4	Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2/3	https://conductscience.org/library/genes/5156	Drugs and targets

1 to 10 of 178

See all 178 targets

Trials145

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01183780	A Study in Second Line Metastatic Colorectal Cancer	Phase 3	1,072	2015-07-15	Colorectal Cancer	FLUOROURACIL, IRINOTECAN, LEUCOVORIN, RAMUCIRUMAB	Its record names the disease	ClinicalTrials.gov
NCT01767857	A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer	Phase 3	643	2021-06-29	Metastatic Colorectal Cancer	BERMEKIMAB	Its record names the disease	ClinicalTrials.gov
NCT02983045	A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors	Phase 1/2	557	2023-03-13	Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Triple Negative Breast Cancer, HR+/HER2- Breast Cancer, Gastric Cancer	BEMPEGALDESLEUKIN, IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT02563002	Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)	Phase 3	307	2022-03-16	Colorectal Carcinoma	BEVACIZUMAB, CETUXIMAB, FLUOROURACIL, LEUCOVORIN CALCIUM, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01830621	BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma	Phase 3	282	2019-03-11	Colorectal Carcinoma	NAPABUCASIN	Its record names the disease	ClinicalTrials.gov
NCT04332653	NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors	Phase 1/2	215	2026-02-09	Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer	EFINEPTAKIN ALFA, PEMBROLIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02437136	Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)	Phase 1/2	191	2025-03-20	Non-Small Cell Lung Cancer, Melanoma, Mismatch Repair-Proficient Colorectal Cancer	ENTINOSTAT, PEMBROLIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02337946	Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma	Phase 2	164	2019-03-01	Colorectal Carcinoma	FLUOROURACIL, LEVOLEUCOVORIN CALCIUM, OXALIPLATIN, PANITUMUMAB	Its record names the disease	ClinicalTrials.gov
NCT02460198	Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)	Phase 2	124	2020-08-21	Colorectal Carcinoma	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00405587	Safety Study of PLX4032 in Patients With Solid Tumors	Phase 1	109	2017-08-22	Malignant Melanoma, Colorectal Carcinoma	VEMURAFENIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 145

See all 145 trials

Comparisons in its trials35

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
FOLFIRI + Ramucirumab vs FOLFIRI + Placebo: serious adverse events	198 of 529	175 of 528	1,057	NCT01183780	Trial comparisons
Xilonix vs Placebo: deaths from any cause	28 of 411	13 of 200	611	NCT01767857	Trial comparisons
Xilonix vs Placebo: serious adverse events	169 of 411	84 of 200	611	NCT01767857	Trial comparisons
Part 2 Dose Expansion: NKTR-214 (0.006 mg/kg) q3w + Nivolumab (360 mg) q3w vs Part 4 Dose Expansion of NKTR-214 + Nivolumab + Ipilimumab: Part 2 and Part 4: Objective Response Rate (ORR) Per RECIST 1.1 at Recommended Phase 2 Dose (RP2D)	64 of 429	3 of 17	446	NCT02983045	Trial comparisons
Pembrolizumab vs Standard of Care (SOC): Number of Participants Who Discontinued Study Treatment Due to an AE	21 of 153	20 of 143	296	NCT02563002	Trial comparisons
Pembrolizumab vs Standard of Care (SOC): Number of Participants Who Experienced an Adverse Event (AE)	149 of 153	142 of 143	296	NCT02563002	Trial comparisons
BBI608 vs Placebo: Disease Control Rate	17 of 138	18 of 144	282	NCT01830621	Trial comparisons
BBI608 vs Placebo: Number of Patients With Adverse Events	135 of 136	139 of 144	280	NCT01830621	Trial comparisons
BBI608 vs Placebo: deaths from any cause	127 of 136	130 of 144	280	NCT01830621	Trial comparisons
BBI608 vs Placebo: serious adverse events	40 of 136	29 of 144	280	NCT01830621	Trial comparisons

1 to 10 of 35

See all 35 comparisons in its trials

Papers from its trials82

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37141828	RESULT	1	PubMed
31725351	RESULT	1	PubMed
29397354	RESULT	1	PubMed
26124477	RESULT	1	PubMed
24943235	RESULT	1	PubMed
23690424	RESULT	1	PubMed
20818844	RESULT	1	PubMed
20603436	RESULT	1	PubMed
19273701	RESULT	1	PubMed
19196673	RESULT	1	PubMed

1 to 10 of 82

See all 82 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0024331

GET https://conductscience.org/api/diseases/v1/MONDO_0024331/drugs?page=2

API reference For AI assistants